BRCA1 and digestive system neoplasm: While we were limited in sample size, our data indicate HRDetect that combines multiple genomic signatures may be more specific for identification of BRCA1/2-deficient tumors and platinum treatment duration compared to each signature individually, particularly in GI tumors.